To graphically illustrate the cumulative risk of relapse and breast cancer specific death in the main analysis, (i.e. patients with decreased CYP2D6 activity (50% or less), compared to CYP2D6*1/*1), Kaplan Meier curves in the full cohort are presented in Figures 2 and 3, for the purely tamoxifen treated subgroup in Figures 4 and 5 and for the subgroup of premenopausal women with tamoxifen as their only endocrine treatment in Supplementary Figures 5 and 6. This evidence concerns the gene CYP2D6 and breast carcinoma.